Biotech Values

[bladerunner1717]

MEIP completes offering



December 17, 2014 - 4:05 PM EST


MEI Pharma Completes Public Offering of Common Stock
SAN DIEGO, Dec. 17, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares of common stock that were issued upon exercise, in full, of the option to purchase additional shares granted to the underwriters. Exercise of the full option to purchase additional shares by the underwriters increased the gross proceeds to the Company, before underwriting discounts and expenses, from approximately $40.0 million to approximately $46.0 million.

MEI Pharma Logo.
The Company intends to use the net proceeds from this offering to progress the clinical development programs for Pracinostat in acute myeloid leukemia (AML) and for other general corporate purposes.

BofA Merrill Lynch acted as sole book-running manager for the offering. Cowen and Company and Stifel acted as co-lead managers and Wedbush PacGrow Life Sciences acted as co-manager. ROTH Capital Partners served as financial advisor to the Company.

Bladerunner